Cyproheptadine

Cyproheptadine is a first-generation, sedating antihistamine belonging to the tricyclic benzocycloheptene chemical class ^[2]. Unlike a simple allergy drug, it carries an unusually broad pharmacological profile: in addition to blocking histamine it is a potent antagonist of serotonin receptors and also has anticholinergic and mild antidopaminergic actions ^[1][2]. This mixture of activities is what lets a single molecule be used across a surprisingly wide range of conditions ^[2].

The drug was patented in the late 1950s and approved for medical use in the early 1960s, initially as a treatment for allergic complaints such as hay fever, hives, and itching ^[2]. As with other older antihistamines, its sedating quality has also led to occasional use as a sleep aid ^[2].

One of its best-known secondary uses is as an appetite stimulant. Because serotonin signaling normally suppresses appetite, blocking it tends to increase hunger, and cyproheptadine has been given to promote weight gain in people with poor appetite ^[2]. Controlled trials and systematic reviews, including studies in children and adults with cystic fibrosis, have found that it can produce modest but real increases in weight and reported appetite, generally with only mild sedation as a side effect ^[3][4].

Its serotonin-blocking action underlies several other applications. It is used to help prevent migraine headaches, and it is a standard antidote for serotonin syndrome, a potentially dangerous reaction to excess serotonergic drug activity ^[1][2]. It has also been used to counter sexual side effects and other problems caused by serotonergic antidepressants and antipsychotics, and it has been tried in conditions such as recurrent vomiting and nightmares ^[2].

Common side effects reflect its antihistamine and anticholinergic nature and include drowsiness, dizziness, dry mouth, and weight gain ^[2]. Cyproheptadine is a long-established, inexpensive generic drug; it is prescription-only in some countries, such as the United States, while being sold over the counter in others ^[2]. It is supplied as tablets and as an oral solution ^[2].

Cyproheptadine is a prescription medicine. Its most common effects are drowsiness and increased appetite, along with dry mouth, dizziness, constipation, blurred vision, and sometimes urinary retention from its anticholinergic action. Older adults are more prone to confusion and falls, and it should be used cautiously in glaucoma, prostate enlargement, and urinary retention. It adds to the sedation of alcohol and other central nervous system depressants, should not be combined with MAO inhibitors, and is generally avoided in newborns and during breastfeeding. Because it can counter serotonin, it may reduce the effect of antidepressants that rely on serotonin.

Cyproheptadine is a first-generation antihistamine that is also a potent 5-HT2 and 5-HT1A antagonist, and both halves generate interactions.

The serotonergic half is the one people miss. Case reports document cyproheptadine reversing the antidepressant effect of fluoxetine and other SSRIs, with depressive symptoms returning within days; 5-HT1A blockade is the likely mechanism. Patients often take it for urticaria, rhinitis or appetite without mentioning it, so the loss of antidepressant response looks unexplained. That same antagonism is what makes cyproheptadine useful as a treatment for serotonin syndrome.

The antihistamine half brings additive sedation with alcohol, benzodiazepines, opioids and other CNS depressants, and additive anticholinergic load with tricyclics, oxybutynin and similar agents, which in older adults shows up as confusion, urinary retention and constipation. Concurrent MAOI use is contraindicated, since MAOIs prolong and intensify the anticholinergic effects of this class.

Checking a whole stack? Run it through interactions + stacks.

Cyproheptadine was developed by Merck and introduced for medical use in the early 1960s, reaching the market under the enduring brand name Periactin as a first-generation antihistamine for allergic conditions. Chemically it is a tricyclic piperidine compound, and early pharmacological study quickly revealed that its activity extended well beyond histamine blockade. Investigators found it to be one of the more potent serotonin antagonists then available, blocking 5-HT2 receptors strongly enough that it became a classic pharmacological tool for probing serotonin's roles in the body.

This antiserotonergic action underpinned several of its distinctive off-label uses that emerged over the following decades, including appetite stimulation, migraine prophylaxis, and treatment of serotonin syndrome. Brain imaging studies later confirmed that oral cyproheptadine occupies a substantial fraction of central 5-HT2 receptors, cementing its status as a broadly acting, multi-receptor agent.

Cyproheptadine has earned lasting affection among clinicians for its versatility, functioning as an allergy medication, an appetite stimulant, a migraine preventive in children, and a practical antidote for serotonin syndrome. Its ability to blunt the effects of excess serotonergic activity, including some of the sexual side effects of antidepressants, makes it a genuinely useful multi-tool that few single drugs can match.

Pediatricians and others value its long safety record and low cost, and its appetite-boosting effect is welcomed in patients struggling to gain weight. The candid trade-offs are the sedation and dry mouth that come with its potent antihistamine and anticholinergic actions, which limit its appeal for people who need to stay alert. Understood as an older, broadly acting agent rather than a targeted modern drug, cyproheptadine remains a reliable and often clever therapeutic choice.